Pfizer: increase in clawback exceeds increase in revenue
…in 2017. Almost all of the company’s revenue comes from reimbursed drugs, according to Ziarul Financiar. The company estimates that the increase in the clawback tax exceeded that in revenue and that the figure will come to RON 86m (€17m) in 2017 (from RON 68m or €15m in 2016).
Sign up now to open the entire news item.You are allowed to open only one news item from PMR websites.
(to send requested information)
(required for new e-mails only)